Trials / Withdrawn
WithdrawnNCT06145399
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging In Patients Advanced Breast Cancer
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.
Conditions
- Breast Cancer
- Breast Carcinoma
- Metastatic Breast Cancer
- Metastatic Breast Carcinoma
- Female Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F-FDG PET/CT | Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners |
| DIAGNOSTIC_TEST | [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging | 18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions. |
| DRUG | 18F-FDHT | 18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions. |
Timeline
- Start date
- 2023-10-24
- Primary completion
- 2024-04-29
- Completion
- 2024-04-29
- First posted
- 2023-11-24
- Last updated
- 2025-05-18
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06145399. Inclusion in this directory is not an endorsement.